NOVO.B.DK

288.55

+0.65%↑

GMAB.DK

1,716.5

+4%↑

HLUNB.DK

41.28

+2.94%↑

ZEAL.DK

316.4

+4.6%↑

AMBUB.DK

66.45

+2.15%↑

NOVO.B.DK

288.55

+0.65%↑

GMAB.DK

1,716.5

+4%↑

HLUNB.DK

41.28

+2.94%↑

ZEAL.DK

316.4

+4.6%↑

AMBUB.DK

66.45

+2.15%↑

NOVO.B.DK

288.55

+0.65%↑

GMAB.DK

1,716.5

+4%↑

HLUNB.DK

41.28

+2.94%↑

ZEAL.DK

316.4

+4.6%↑

AMBUB.DK

66.45

+2.15%↑

NOVO.B.DK

288.55

+0.65%↑

GMAB.DK

1,716.5

+4%↑

HLUNB.DK

41.28

+2.94%↑

ZEAL.DK

316.4

+4.6%↑

AMBUB.DK

66.45

+2.15%↑

NOVO.B.DK

288.55

+0.65%↑

GMAB.DK

1,716.5

+4%↑

HLUNB.DK

41.28

+2.94%↑

ZEAL.DK

316.4

+4.6%↑

AMBUB.DK

66.45

+2.15%↑

Kodu・Aktsiate loetelu・Coloplast A-S (Class B)

Coloplast A-S (Class B)

Suletud

411.3 2.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

399.8

Max

413.5

Põhinäitajad
By Trading Economics
Sissetulek	-2.4B -971M
Müük	41M 7.1B
P/E Sektori keskmine	43.298 49.701
Aktsiakasum	-4.309
Dividenditootlus	5.69
Kasumimarginaal	-13.707
Töötajad	17,083
EBITDA	2.8B 5.1B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+11.86% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	5.69% 2.39%

Turustatistika
By TradingEconomics
Turukapital	856M 91B
Eelmine avamishind	409.09
Eelmine sulgemishind	411.3

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. mai 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. mai 2026, 22:52 UTC

Suurimad hinnamuutused turgudel

Osisko Shares Fall on Planned Convertible Notes Offering

20. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. mai 2026, 23:44 UTC

Tulu

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. mai 2026, 23:14 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. mai 2026, 22:10 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. mai 2026, 22:00 UTC

Tulu

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. mai 2026, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. mai 2026, 21:27 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. mai 2026, 21:20 UTC

Tulu

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. mai 2026, 21:19 UTC

Tulu

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. mai 2026, 21:18 UTC

Tulu

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. mai 2026, 21:17 UTC

Tulu

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. mai 2026, 21:16 UTC

Tulu

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK 11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Coloplast A-S (Class B) aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.